Abcuro is a clinical-stage biotechnology company developing ulviprubart, a first-in-class medicine in clinical development, designed to treat autoimmune diseases including inclusion body myositis (IBM). IBM is an autoimmune disease in which highly cytotoxic T cells chronically attack muscle tissue, leading to progressive weakness and limb muscle atrophy. Patients with IBM progressively lose muscle function, including loss of grip, dexterity, mobility and even swallowing — all of which affect the quality of life of these individuals in a devastating way. Abcuro’s mission is to advance ulviprubart, an anti-KLRG1 antibody capable of selectively depleting highly cytotoxic T cells, to address this progressive condition, which currently has no approved treatment options. Ulviprubart is currently being evaluated in a registrational Phase 2/3 clinical trial, also known as the MUSCLE trial, in IBM, as well as a Phase 1/2 clinical trial in T cell large granular lymphocytic leukemia (T-LGLL).
MassBio Member Spotlight: Abcuro
Location: Newton, MA
Website: abcuro.com
Leadership: Alex Martin (CEO); H. Jeffrey Wilkins, MD (CMO); Karen Tubridy, PharmD (COO)
Therapeutic area(s): Autoimmune Disease (inclusion body myositis, or IBM); Oncology (T cell large granular lymphocytic leukemia, or T-LGLL)